Treatment of Hypertension in Patients With HF With Preserved LVEF Most patients with HF and preserved LVEF (HFpEF), es- pecially elderly women, have hypertension. A significant proportion of these patients also have evidence of LV hy- pertrophy, and some may have atrial dilatation, cardiac enlargement, and wall motion abnormalities without LV systolic dysfunction. Patients with HFpEF may respond particularly well to the treatment of hypertension with regression of hypertrophy84 and improvement in filling Most patients with HFpEF require treat- ment with cardiac medications for the comorbidities of hypertension, diabetes mellitus, coronary artery dis- ease, and atrial fibrillation. The 2013 HF guidelines sug- gest that the use of -blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control BP in patients with HFpEF.8 The use of ARBs might also be considered to decrease hospitalizations for patients with HFpEF.8 Recommendations Harmonized With Existing Guidelines for the Recognition and Treatment of Patients With HF With Hypertension See Tables 2 through 4 for a summary of these recom- mendations. Stage A HF For patients with hypertension who are at high risk for developing HF in the future but with no functional or structural cardiac disorder at present time, the following is recommended: 1. Hypertension should be controlled in accor- dance with contemporary guidelines to lower the risk of developing HF (Class I; Level of Stage B HF For patients with hypertension, with cardiac structural abnormalities or remodeling who have not developed HF symptoms, the following is recommended: 1. 